Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, with reference to the World Federation of Haemophilia’s annual global survey, published in 2016, for what reason (a) Factor VIII and (b) Factor IX consumption per capita is lower in the UK than Ireland; and what assessment he has made of the adequacy of UK levels of factor (i) VIII and (ii) IX consumption to deliver appropriate outcomes for patients.

NHS England commissions treatments for haemophilia A and haemophilia B, and other bleeding disorders, according to the current British Society for Haematology clinical guidelines. Commissioned services report outcomes via a quality dashboard. Based on the data, NHS England considers that haemophilia population outcomes are adequate, and therefore has not undertaken an assessment of the adequacy of factor levels. This will continue to be monitored as new data becomes available.